Axonics Brand Guidelines: Irvine’s Rechargeable Sacral Stimulator Maker, Now Boston Scientific

A sacral nerve stimulator from Orange County.

Axonics began in Irvine, California. The trade blog Implantable Device described Axonics Modulation Technologies in March 2019 as an Irvine company founded in 2013 that had developed an implantable sacral nerve stimulator for people with urinary and bowel dysfunction. Its company releases from 2019 name Raymond W. Cohen as chief executive.

Its field is sacral neuromodulation, or SNM. Boston Scientific, in its January 2024 announcement, described SNM as a minimally invasive procedure that delivers mild electrical pulses to the sacral nerve, used in the treatment of overactive bladder and fecal incontinence. When Axonics started, the market already had an incumbent: Implantable Device noted in 2019 that Medtronic’s InterStim II was then the only sacral neurostimulator approved in the United States, and that Axonics’s application referred to it.

The company’s first device was the Axonics r-SNM System, which Implantable Device described as a miniaturised, rechargeable implantable stimulator with a charging system and a remote control and programming interface. It received the CE mark in June 2016, according to the same report, and Axonics pursued US approval through what it called a literature-based premarket approval submission, backed by one-year data from a European study.

By 2019 the company was listed on Nasdaq under the ticker AXNX, according to its November 2019 release.

From r-SNM to the F15 and R20.

The American approvals came in two steps in 2019. In September 2019 the FDA approved the r-SNM System for fecal incontinence, and on 14 November 2019 Axonics announced premarket approval for overactive bladder and urinary retention, according to the company’s release of that date, republished by its investor Gilde Healthcare. The company said the approval was supported by its ARTISAN-SNM pivotal study, run at 14 centres in the United States and five in Western Europe. The release said the first filing had gone to the FDA in December 2018, followed by amendments including further test data and the full six-month study data, and that the agency had carried out two audits of the company’s quality system and manufacturing during the review. It described the stimulator as “approximately the size of a USB stick” and listed a tined lead, a wireless charging system, a small key-fob patient remote and a clinician programmer among the parts of the system.

Axonics presented itself as the rechargeable alternative. Its 2019 release called the r-SNM System the first rechargeable SNM system approved for sale in the United States, Europe, Canada and Australia — a claim made by the company itself.

Later generations followed under simpler names. Boston Scientific’s January 2024 announcement listed the Axonics R20 and Axonics F15 systems as the devices used to deliver SNM therapy, and said Axonics had received FDA approval in January 2023 for its fourth-generation R20 neurostimulator, a rechargeable device. The same announcement noted a product from outside neuromodulation: the Bulkamid urethral bulking system, for female stress urinary incontinence.

That mix — implants, accessories and a bulking agent — gave Axonics a portfolio aimed at urologists, urogynecologists and colorectal surgeons, the specialists its 2019 release named as its sales force’s main audience. That release said the US commercial team numbered 146 territory managers, clinical support specialists and sales managers, and that it was calling on the top 1,000 such specialists in the country.

How neurotech presents itself.

Neuromodulation companies sell devices that most people will never see. Spinal cord stimulators, sacral nerve stimulators, hypoglossal nerve implants and brain-computer interfaces sit under the skin or inside the skull, so the companies that make them have to show something else: the scale of the device, the place it sits in the body, and the people it is meant for.

A few images recur across the category. Implants are often photographed held between fingertips or beside a coin or a key fob, to make their size legible. X-ray-style renders show thin leads running along a spine or curving toward a nerve, with the generator drawn as a small rounded shape. Patient pages tend to use calm portraits at home, on walks or with family, rather than hospital scenes.

Brain-computer interface start-ups lean in another direction: glowing renders of the brain, electrode arrays magnified many times over, and photographs of lab benches, engineers and surgical teams. Their audience includes investors and researchers as much as doctors, and the imagery often reads as a promise about the future rather than a product shot.

The category also has its own meeting places. Trade congresses such as the North American Neuromodulation Society (NANS) meeting, the International Neuromodulation Society (INS) congress and the Society for Neuroscience annual meeting are where companies show booths, posters and new hardware to clinicians and scientists. This guide sets out what can be checked about each company — founding, ownership, products and approvals as dated sources state them — and marks clearly what rests only on the company’s own word.

No longer independent since November 2024.

Axonics is no longer an independent company. On 8 January 2024 Boston Scientific, based in Marlborough, Massachusetts, announced a definitive agreement to acquire Axonics, Inc., then listed on Nasdaq, describing it as a medical technology company focused on devices for urinary and bowel dysfunction. Boston Scientific expected at the time to complete the deal in the first half of 2024; it announced the close of the acquisition on 15 November 2024.

Boston Scientific placed Axonics in its Urology business. Announcing the close, Meghan Scanlon, president of Boston Scientific’s Urology division, said the Axonics portfolio enabled the company to expand into sacral neuromodulation, which she called a high-growth adjacency for the Urology business, and to offer treatment options based on patients’ life stage and the severity of their incontinence.

The brand’s own address has gone with it. In November 2026 the axonics.com domain forwards visitors to Boston Scientific’s US website, and the product names used in Boston Scientific’s announcements — Axonics R20 and Axonics F15 — keep the Axonics name as a product label inside the larger company rather than as a separate corporate identity.

The arc is short: a 2013 start-up in Irvine, a European approval in 2016, two American approvals in 2019, a Nasdaq listing, then purchase by Boston Scientific about eleven years after its founding. In its own releases the company set its small rechargeable implant against the incumbent’s non-rechargeable device, and that contrast was the core of how it described itself.

For a design guide, Axonics shows how a focused device maker can turn one product attribute into a whole identity, and how that identity becomes a product label after an acquisition. Compare Boston Scientific, its owner since 2024, and Medtronic, maker of the InterStim system. For this guide we use a deep plum, a pale lilac and a warm copper with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Axonics’s identity on hand — save it to a board in the Made Good inspiration library.